Business / Finance

RSS

Dr. Reddy’s acquires GSK's US penicillin facility and products

Dr. Reddy's Laboratories today announced the completion of the acquisition of GlaxoSmithKline's United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010.

30 Mar 2011

TAP announces new corporate identity

The Automation Partnership, a leading supplier of innovative automation for life science applications today announced that the company will now be known as TAP Biosystems.

30 Mar 2011

Cephalon receives unsolicited proposal from Valeant

Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.

30 Mar 2011

SCOLR Pharma total revenue decreases 34% to $618,000 for 2010

SCOLR Pharma, Inc. today reported financial results for the twelve months ended December 31, 2010, and also provided updates on a number of key corporate objectives.

30 Mar 2011

CryoLife to acquire Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, and Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of patients with refractory angina resulting from diffuse coronary artery disease, today announced that the boards of directors of both companies have approved a definitive agreement under which CryoLife will acquire all of the outstanding shares of Cardiogenesis for $0.457 per share.

29 Mar 2011

Medwell announces service agreement with Spectral Diagnostics

Medwell Capital Corp. today announced that the service agreement under which Medwell provides clinical, regulatory and capital markets consulting services to Spectral Diagnostics has been increased to $1.5 million per year, from $1.0 million, effective January 2011, in exchange for an increased level of service.

29 Mar 2011

Elbit Imaging consolidated revenue is NIS 1,474 million for 2010

Elbit Imaging Ltd. announced today its results for the year 2010. Consolidated revenues in Year 2010 were NIS 1,474 million compared to NIS 698 million reported last year.

29 Mar 2011

Arena to sell 12,150,000 shares of its common stock

Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 12,150,000 shares of its common stock, at a price of $1.46 per share, and 12,150 shares of its Series C Convertible Preferred Stock, at a price of $1,460 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization.

29 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

Lotus fiscal year revenue increases 28.7% to $72.7 million for 2010

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2010.

29 Mar 2011

EpiCept enters agreement with institutional investor to purchase 7.1 million shares of common stock

EpiCept Corporation announced today that it has entered into a definitive agreement with an institutional investor for the purchase of approximately 7.1 million shares of its common stock at $0.65 per share, and five and one half year warrants to purchase up to approximately 5.3 million shares of common stock at an exercise price of $0.72 per share that are not exercisable for six months following the closing date of the offering.

29 Mar 2011

GTCR completes Sterigenics acquisition

GTCR, a leading private equity firm, today announced it has successfully completed the acquisition of Sterigenics International, Inc., the leading global provider of contract sterilization and ionization services for medical devices, food products, and advanced applications, from Silverfleet Capital and PPM America Capital Partners.

28 Mar 2011

Alpha II, PCIS Gold enter integration contract

Alpha II, a leader in healthcare coding, compliance and reimbursement, announced today a new integration contract with PCIS Gold, a provider of single-source medical group practice software. Alpha II's ClaimStaker software will enhance coding reliability, while increasing professional and institutional claim validity for PCIS Gold's customers.

28 Mar 2011

Concord Medical fourth quarter total net revenues increase 30.1% to RMB112.9 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2010.

28 Mar 2011

Graymark Healthcare 2010 net revenues increase 30% to $22.8 million

Graymark Healthcare, Inc., the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), reported financial results for the fiscal year ended December 31, 2010.

28 Mar 2011

Quest Diagnostics subsidiary initiates tender offer for Celera acquisition

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced today it has commenced a tender offer through its wholly owned subsidiary, Spark Acquisition Corporation, for all of the outstanding shares of common stock (the "Shares") of Celera Corporation (Nasdaq: CRA), one of the world's pioneers in genetic diagnostics discovery and development for $8.00 per share in cash, without interest and less any required withholding taxes.

From Quest Diagnostics 28 Mar 2011

Biotectix acquires Chameleon BioSurfaces technology

Biotectix, LLC announced today the acquisition of all significant assets owned by Chameleon BioSurfaces Ltd. (Cambridge, United Kingdom). Financial terms were not disclosed.

28 Mar 2011

Helix BioMedix 2010 total revenue increases 118% to $852,000

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the year ended December 31, 2010.

28 Mar 2011

SHOM selects Scott & Co to audit Company's financials for past two years

Southern Home Medical Equipment, Inc., a Holding Company providing healthcare services, healthcare professionals and equipment to medical institutions, has selected Scott & Company, a Public Company Accounting Oversight Board approved accounting firm in Columbia, SC, to audit the Company's financials for the past two years and provide additional accounting services to the Company.

28 Mar 2011

Medwell acquires ownership and control over 6,449,501 common shares of Spectral

Spectral Diagnostics Inc., a Phase III company developing the first theranostic treatment for severe sepsis and septic shock, and Medwell Capital Corp., today jointly announced a non-brokered agreement whereby Medwell and a consortium of buyers purchased in private transactions 12,449,501 common shares and 962,500 common share purchase warrants of Spectral from GrowthWorks Canadian Fund Ltd., representing 15.6% of the issued and outstanding shares.

28 Mar 2011